According to the Surveillance Epidemiology of Coronavirus Under Research Exclusion for inflammatory Bowel Disease (SECURE-IBD) database, an international registry of IBD patients infected with SARS-CoV-2, it has been reported that corticosteroids and mesalamine, rather than tumor necrosis factor-α (TNF-α) antagonists are associated with an increased risk of COVID-19 in IBD patients (12, 13). This evidence concerns the gene TNF and inflammatory bowel disease.